ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Vertex Pharmaceuticals has acquired Crinetics Pharmaceuticals for $10 billion, despite Crinetics having near zero revenue. There is speculation about potential buyers for PSS, with suggestions that a significant offer from a big pharma company like Amgen or Pfizer could be problematic. Regardless, it is believed that going it alone could result in significant returns, especially when EAP for All Cancer Lymphopenia is fully approved. Immunitybio has a patent on M-ceNK cells, which has been recently discovered. There is excitement and anticipation for what is to come for IBRX.